UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

Diabetes, obesity & metabolism, 2009-08, Vol.11 (8), p.786-794

2009

Volltextzugriff (PDF)

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

Diabetic medicine, 2010-12, Vol.27 (12), p.1409-1419

2010

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

Journal of clinical pharmacology, 2008-10, Vol.48 (10), p.1171-1178

2008

Volltextzugriff (PDF)

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease

Diabetologia, 2007-09, Vol.50 (9), p.1930-1937

2007

Volltextzugriff (PDF)

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

Current medical research and opinion, 2009-08, Vol.25 (8), p.1963-1972

2009

Volltextzugriff (PDF)

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

Diabetes, obesity & metabolism, 2011-03, Vol.13 (3), p.258-267

2011

Volltextzugriff (PDF)

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study

Diabetic medicine, 2011-11, Vol.28 (11), p.1352-1361

2011

Volltextzugriff (PDF)

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes, obesity & metabolism, 2011, Vol.13 (1), p.65-74

2011

Volltextzugriff (PDF)

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes, obesity & metabolism, 2011-07, Vol.13 (7), p.653-661

2011

Volltextzugriff (PDF)

Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes

Clinical endocrinology (Oxford), 2009-07, Vol.71 (1), p.27-32

2009

Volltextzugriff (PDF)

Recurrent deep venous thrombosis caused by congenital interruption of the inferior vena cava and heterozygous factor V Leiden mutation

Journal of internal medicine, 2002-09, Vol.252 (3), p.276-280

2002

Volltextzugriff (PDF)

The Gutenberg Health Study

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2012-06, Vol.55 (6-7), p.824-829

2012

Volltextzugriff (PDF)

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

Diabetes, obesity & metabolism, 2012-04, Vol.14 (4), p.348-357

2012

Volltextzugriff (PDF)

In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL

Arteriosclerosis, thrombosis, and vascular biology, 2000-03, Vol.20 (3), p.793-800

2000

Volltextzugriff (PDF)

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.542-550

2011

Volltextzugriff (PDF)

Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin

International journal of clinical pharmacology and therapeutics, 2010-06, Vol.48 (6), p.367-374

2010

Volltextzugriff (PDF)

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.276-284

2015

Volltextzugriff (PDF)

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers

International journal of clinical pharmacology and therapeutics, 2010-10, Vol.48 (10), p.652-661

2010

Volltextzugriff (PDF)

Novel site in lipoprotein lipase (LPL415;-438) essential for substrate interaction and dimer stability

Journal of lipid research, 2001-08, Vol.42 (8), p.1180-1186

2001

Volltextzugriff (PDF)

Human lipoprotein lipase: the loop covering the catalytic site is essential for interaction with lipid substrates

The Journal of biological chemistry, 1992-12, Vol.267 (35), p.25086-25091

1992

Volltextzugriff (PDF)

Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia

The American journal of cardiology, 1996-03, Vol.77 (8), p.575-580

1996

Volltextzugriff (PDF)

The Endothelium and Lipoproteins: Insights from Recent Cell Biology and Animal Studies

Seminars in thrombosis and hemostasis, 2000, Vol.26 (5), p.521-528

2000

Volltextzugriff (PDF)

Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome

Arteriosclerosis, thrombosis, and vascular biology, 1997-07, Vol.17 (7), p.1400-1406

1997

Volltextzugriff (PDF)

Low hepatic lipase activity is a novel risk factor for coronary artery disease

Circulation (New York, N.Y.), 2001-12, Vol.104 (25), p.3057-3062

2001

Volltextzugriff (PDF)

A novel A-->G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency

Journal of lipid research, 1996-06, Vol.37 (6), p.1213-1223

1996

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(56)

Publikationsform

Sprache

Englisch
(69)
Deutsch
(11)

Erscheinungsjahr

n.n

Thema

Humans
(54)
Life Sciences & Biomedicine
(53)
Science & Technology
(53)
Male
(40)
Middle Aged
(29)
Adult
(26)
Female
(25)
Endocrinology & Metabolism
(20)
Biological And Medical Sciences
(19)
Aged
(18)
Linagliptin
(17)
Medical Sciences
(15)
Cardiovascular System & Cardiology
(13)
Diabetes Mellitus, Type 2 - Drug Therapy
(12)
Diabetes
(11)
Peripheral Vascular Disease
(11)
Type 2 Diabetes
(11)
Diabetes Mellitus, Type 2 - Blood
(10)
Liver - Enzymology
(10)
Biochemistry & Molecular Biology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes

Recurrent deep venous thrombosis caused by congenital interruption of the inferior vena cava and heterozygous factor V Leiden mutation

The Gutenberg Health Study

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers

Novel site in lipoprotein lipase (LPL415;-438) essential for substrate interaction and dimer stability

Human lipoprotein lipase: the loop covering the catalytic site is essential for interaction with lipid substrates

Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia

The Endothelium and Lipoproteins: Insights from Recent Cell Biology and Animal Studies

Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome

Low hepatic lipase activity is a novel risk factor for coronary artery disease

A novel A-->G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency

Suchergebnisse filtern